IRIS
MORISCO, FILOMENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.054
NA - Nord America 11.513
EU - Europa 7.180
SA - Sud America 1.647
Continente sconosciuto - Info sul continente non disponibili 402
AF - Africa 323
OC - Oceania 18
Totale 33.137
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.011
SG - Singapore 5.631
RU - Federazione Russa 3.487
CN - Cina 2.181
VN - Vietnam 2.117
BR - Brasile 1.326
IT - Italia 1.032
HK - Hong Kong 948
FR - Francia 460
DE - Germania 418
UA - Ucraina 350
FI - Finlandia 321
NL - Olanda 279
CA - Canada 253
GB - Regno Unito 221
IN - India 198
JP - Giappone 182
SE - Svezia 170
BD - Bangladesh 164
IE - Irlanda 143
AR - Argentina 131
MX - Messico 103
KR - Corea 102
ZA - Sudafrica 82
IQ - Iraq 78
CI - Costa d'Avorio 75
ES - Italia 63
PL - Polonia 57
AT - Austria 54
PH - Filippine 53
ID - Indonesia 49
TH - Thailandia 48
TR - Turchia 47
EC - Ecuador 45
PK - Pakistan 38
CO - Colombia 36
VE - Venezuela 35
CL - Cile 30
MA - Marocco 30
TW - Taiwan 27
CR - Costa Rica 26
EG - Egitto 26
JM - Giamaica 26
LT - Lituania 25
PY - Paraguay 25
JO - Giordania 23
AE - Emirati Arabi Uniti 18
KE - Kenya 18
UZ - Uzbekistan 18
HN - Honduras 16
NG - Nigeria 15
SA - Arabia Saudita 15
NP - Nepal 14
AU - Australia 13
DZ - Algeria 13
TN - Tunisia 13
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
NI - Nicaragua 11
PS - Palestinian Territory 11
RO - Romania 11
BE - Belgio 10
ET - Etiopia 10
MY - Malesia 10
AL - Albania 9
KG - Kirghizistan 9
CZ - Repubblica Ceca 8
GT - Guatemala 8
IL - Israele 8
PE - Perù 8
BB - Barbados 7
EU - Europa 7
KZ - Kazakistan 7
LB - Libano 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
BS - Bahamas 6
GR - Grecia 6
LV - Lettonia 6
XK - ???statistics.table.value.countryCode.XK??? 6
CH - Svizzera 5
HU - Ungheria 5
OM - Oman 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
BW - Botswana 4
CY - Cipro 4
LC - Santa Lucia 4
PA - Panama 4
PR - Porto Rico 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
BG - Bulgaria 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
DK - Danimarca 3
GA - Gabon 3
GH - Ghana 3
GP - Guadalupe 3
Totale 32.655
Salva come PNG Salva come JPEG
Città #
Singapore 2.615
San Jose 1.759
Hong Kong 923
Ashburn 858
Moscow 855
Chandler 658
Ho Chi Minh City 588
Beijing 503
Santa Clara 493
Hanoi 453
Hefei 417
The Dalles 395
Lauterbourg 331
Los Angeles 323
Millbury 310
Council Bluffs 298
Jacksonville 289
Princeton 255
Naples 244
Amsterdam 230
Boston 227
New York 221
Buffalo 207
Nanjing 184
Tokyo 158
Des Moines 118
Phoenix 105
São Paulo 103
Redondo Beach 99
Dallas 98
Munich 96
Napoli 94
Da Nang 90
Haiphong 89
Dong Ket 88
Wilmington 82
Frankfurt am Main 79
Seoul 72
Ottawa 71
Nanchang 68
Chicago 67
Seattle 65
Orem 59
Mexico City 57
Toronto 56
Lawrence 54
Atlanta 53
Milan 52
Rio de Janeiro 49
Warsaw 48
Kochi 47
Denver 44
Brooklyn 43
Helsinki 42
London 42
Nuremberg 42
Shenyang 41
Hebei 40
Montreal 39
Houston 38
Johannesburg 37
Turku 37
Rome 35
Stockholm 35
Dublin 33
Norwalk 32
Poplar 32
Washington 32
Boardman 31
San Francisco 31
Tianjin 31
Düsseldorf 29
Jiaxing 27
Baghdad 26
Biên Hòa 26
Brasília 26
Vienna 26
Chennai 25
Falkenstein 25
Hải Dương 25
Kronberg 25
Thái Nguyên 23
Manchester 22
San José 22
Charlotte 21
Porto Alegre 21
Shanghai 21
Can Tho 20
Amman 19
Changsha 19
Kunming 18
Bangkok 17
Dhaka 17
Mumbai 17
Newark 17
Ninh Bình 17
Salvador 17
Tashkent 17
Woodbridge 17
Belo Horizonte 16
Totale 17.108
Salva come PNG Salva come JPEG
Nome #
Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins 459
The combination of berberine, tocotrienols and coffee extracts improves metabolic profile and liver steatosis by the modulation of gut microbiota and hepatic mir‐122 and mir‐34a expression in mice 447
Decaffeinated coffee reduces gut leakiness in rats fed with high-fat diet. The role of Occludin and Zonulin-1 237
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 211
Metabolic-associated fatty liver disease (MAFLD) in coeliac disease 204
Apple polyphenol extracts prevent damage to human gastric epithelial cells in vitro and to rat gastric mucosa in vivo 201
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 187
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 186
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 179
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 179
Anti-HDV reflex testing in HBsAg-positive subjects: An efficacious strategy to identify HDV infection 173
Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. 168
Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania 167
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 163
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 159
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 158
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life 157
A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C 156
Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma 154
Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis 151
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 146
Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study 146
Use of Telemedicine for chronic liver disease at a single care center during the COVID-19 pandemic: Prospective observational study 146
Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency 145
Pattern of macrovascular invasion in hepatocellular carcinoma 144
Decaffeinated coffee consumption induces expression of tight junction proteins in high fat diet fed rats 143
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 142
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 142
CIRANAD (Centro Interuniversitario per Ricerche su Alimenti Nutrizione ed Apparato Digerente) 142
Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival 141
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 141
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 140
Alfa-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to inteferon therapy? 140
L'avvento degli inibitori delle proteasi nella terapia dell'infezione da epatite C: Reazioni avverse dermatologiche 140
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 140
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors 139
Non-invasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis 139
Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents 138
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 138
Berberis aristata, elaeis guineensis and coffea canephora extracts modulate the insulin receptor expression and improve hepatic steatosis in NAFLD patients: A pilot clinical trial 137
Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades 135
Effectiveness of Hepatitis B Vaccination Campaign in Italy: Towards the Control of HBV Infection for the First Time in a European Country 134
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 134
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 134
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 134
Metabolic disorders across hepatocellular carcinoma in Italy 134
Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats 134
Circulating SCCA–IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients 132
Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease 132
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 131
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 130
Coffee and Intestinal Permeability in a Mice Model of Non-Alcoholic Fatty Liver Disease 130
Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma 129
Hepatitis-C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the Study of the Liver) 129
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 129
Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice 129
Prevalence of and risk factors for HBV infection in a metropolitan Southern Italian area: Evidence for the effectiveness of universal Hepatitis B vaccination 128
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 128
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 127
Decaffeinated Coffee Reduces Body Weight Gain in Rats Fed With a Hfd by Modulating Intestinal Gpr41 and CCK Expression 127
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 127
Reactivation of hepatitis B or C in patients with IBD receiving immunosuppressive drugs. A multicentre study 126
Coffee and liver health 126
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 126
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 126
Long-term safety of anti-TNF-? in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. 125
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection 125
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 125
Timing strategies of direct-acting antivirals and biologics administration in HCV-infected subjects with inflammatory bowel diseases 125
Plasma phospholipid dysregulation in patients with cystathionine-β synthase deficiency 125
Decaffeinated Coffee Reduces Intestinal Leakiness in Rats Fed With a Hfd by Modulating Occludin and Zonulin-1 Expression 124
Osteoporosis across chronic liver disease 124
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 123
Vitamin D levels and chronic hepatitis C 123
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. 123
Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage 123
Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection 122
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma 122
COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study 122
Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD 121
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma 121
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 121
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 121
Ultrasound-based transient elastography improves the detection of liver disease in common variable immunodeficiency 121
Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients 120
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 120
Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline 120
Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions 120
Garlic extract prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase. 120
Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. 120
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma 120
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial 119
Association of Very Rare NOTCH2 Variants with Clinical Features of Alagille Syndrome 119
Acute Delta Hepatitis in Italy spanning three decades (1991-2019): Evidence for the effectiveness of the hepatitis B vaccination campaign 119
Vitamin D-PTH axis in HCV infection 119
Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus 119
BIOCHEMICAL MARKERS OF OXIDATIVE STRESS IN PERIPHERAL LYMPHOCYTES OF PATIENTS WITH HCV-RELATED LIVER DESEASES. 118
The interpretation of liver function tests in pregnancy 118
Platelets and hepatocellular cancer: Bridging the bench to the clinics 117
ONLINE ANALYSIS OF BREATH BY PROTON TRANSFER REACTION TIME OF FLIGHT MASS SPECTROMETRY IN CIRRHOTIC PATIENTS 116
Totale 14.416
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.307 0 0 14 2 1 21 15 52 125 61 281 735
2022/20231.631 320 90 17 115 230 181 12 133 221 223 75 14
2023/20241.297 36 245 194 78 40 119 9 134 18 26 269 129
2024/20258.341 458 620 19 72 207 391 810 500 914 859 2.776 715
2025/202616.000 1.761 1.278 1.585 1.349 2.667 688 1.605 1.058 1.940 974 352 743
2026/20271.960 894 541 525 0 0 0 0 0 0 0 0 0
Totale 33.137